Sierra oncology, inc. (SRRA)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Sep'14Jun'14
Operating expenses:
Research and development

11,591

21,271

10,113

11,728

10,137

11,046

12,913

8,785

8,334

7,550

7,405

7,194

8,008

5,821

12,323

9,115

6,636

8,027

8,295

4,738

5,296

2,437

12,717

General and administrative

4,544

3,748

3,151

3,479

3,365

3,603

3,138

4,178

3,420

3,255

2,778

3,283

3,146

3,412

2,960

3,831

3,977

3,419

2,738

1,874

1,441

1,043

791

Total operating expenses

16,135

25,019

13,264

15,207

13,502

14,649

16,051

12,963

11,754

10,805

10,183

10,477

11,154

9,233

15,283

12,946

10,613

11,446

11,033

6,612

6,737

3,480

13,508

Loss from operations

-16,135

-25,019

-13,264

-15,207

-13,502

-14,649

-16,051

-12,963

-11,754

-10,805

-10,183

-10,477

-11,154

-9,233

-15,283

-12,946

-10,613

-11,446

-11,033

-6,612

-6,737

-3,480

-13,508

Other income (expense), net:
Changes in fair value of warrant liabilities

16,240

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

7,487

8,630

1,326

503

347

Other income, net

541

-1,478

288

348

325

447

479

582

272

254

225

185

96

92

88

88

83

18

29

-6

25

22

31

Total other income (expense), net

-15,699

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

18

-7,458

-8,636

-1,301

-481

-316

Loss before provision for (benefit from) income taxes, net

-31,834

-47,423

-12,976

-14,859

-13,177

-14,202

-15,572

-12,381

-11,482

-10,551

-9,958

-10,292

-11,058

-9,141

-15,195

-12,858

-10,530

-11,428

-18,491

-15,248

-8,038

-3,961

-13,824

Provision for (benefit from) income taxes, net

78

39

-73

19

-145

81

-5

-421

43

48

37

37

34

107

14

14

8

30

14

1

10

-

-

Net loss and comprehensive loss

-31,912

-47,462

-12,903

-14,878

-13,032

-14,283

-15,567

-11,960

-11,525

-10,599

-9,995

-10,329

-11,092

-9,248

-15,209

-12,872

-10,538

-11,458

-18,505

-15,249

-8,048

-3,961

-13,824

Adjustment to redemption value on redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

222,130

140,880

11,005

5,591

36,833

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-11,458

-266,544

-156,129

-19,053

-9,552

-50,657

Net loss per common share, basic and diluted

-3.14

-22.93

-0.17

-0.20

-7.00

-29.60

-0.21

-0.16

-0.19

-33.03

-0.19

-0.20

-0.26

-0.30

-0.50

-0.43

-0.35

96.49

-11.03

-104.10

-12.83

-9.37

-55.04

Weighted-average shares used in computing net loss per common share, basic and diluted

10,156

-139,584

74,688

74,688

1,862

-201,316

74,347

74,320

59,722

-142,143

52,268

52,268

42,596

30,368

30,331

30,191

30,070

30,445

24,167

1,499

1,485

1,019

920